Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects - A randomised open-label cross-over study

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 6, 2015, Pages 719-730

  Sakurai, Y ^a   Mori, Y ^a   Okamoto, H ^a   Nishimura, A ^a   Komura, E ^a   Araki, T ^a   Shiramoto, M ^b  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b LTA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; ESOMEPRAZOLE; RABEPRAZOLE; VONOPRAZAN; 1-(5-(2-FLUOROPHENYL)-1-(PYRIDIN-3-YLSULFONYL)-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE; PROTON PUMP INHIBITOR; PYRROLE DERIVATIVE; SULFONAMIDE;

ACID INHIBITORY EFFECT; ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; GENOTYPE; GOOD CLINICAL PRACTICE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; JAPANESE (PEOPLE); MALE; NAUSEA; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; STOMACH PH; VOMITING; COMPARATIVE STUDY; METHODOLOGY; MIDDLE AGED; PH; STOMACH ACID;

ADULT; CROSS-OVER STUDIES; ESOMEPRAZOLE; GASTRIC ACID; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; PYRROLES; RABEPRAZOLE; RESEARCH DESIGN; SULFONAMIDES;

EID: 84939573904     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13325     Document Type: Article

References (27)

1. Graham DY,. Critical effect of Helicobacter pylori infection on the effectiveness of omeprazole for prevention of gastric or duodenal ulcers among chronic NSAID users. Helicobacter 2002; 7: 1-8.
2. Frazzoni M, De Micheli E, Grisendi A, et al,. Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. Aliment Pharmacol Ther 2003; 17: 235-41.
3. Robinson M,. Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. Int J Clin Pract 2005; 59: 709-15.
4. Malfertheiner P, Mössner J, Fischbach W, et al,. Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. Aliment Pharmacol Ther 2003; 18: 615-25.
5. Sachs G, Shin JM, Munson K, et al,. Review article: the control of gastric acid and Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 1383-401.
6. Mejia A, Kraft WK,. Acid peptic diseases: pharmacological approach to treatment. Expert Rev Clin Pharmacol 2009; 2: 295-314.
7. Shin JM, Inatomi N, Munson K, et al,. Characterization of a novel potassium-competitive acid blocker of the gastric H, K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther 2011; 339: 412-20.
8. Furuta T, Shirai N, Sugimoto M, et al,. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005; 20: 153-67.
9. Graham DY, Shiotani A,. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 321-31.
10. Furuta T, Sugimoto M, Shirai N, et al,. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor. Pharmacogenomics 2007; 8: 1199-210.
11. Wedemeyer R-S, Blume H,. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf 2014; 37: 201-11.
12. Frelinger AL III, Lee RD, Mulford DJ, et al,. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol 2012; 59: 1304-11.
13. Andersson K, Carlsson E,. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther 2005; 108: 294-307.
14. Hori Y, Imanishi A, Matsukawa J, et al,. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther 2010; 335: 231-8.
15. Matsukawa J, Hori Y, Nishida H, et al,. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol 2011; 81: 1145-51.
16. Hori Y, Matsukawa J, Takeuchi T, et al,. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther 2011; 337: 797-804.
17. Sakurai Y, Nishimura A, Kennedy G, et al,. Safety, tolerability, pharma-cokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese/non-Japanese subjects. Clin Transl Gastroenterol 2015; 6: e94; doi: 10.1038/ctg.2015.18.
18. Jenkins H, Sakurai Y, Nishimura A, et al,. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 2015; 41: 636-48.
19. Ashida K, Sakurai Y, Nishimura A, et al,. Randomized clinical trial: A dose-ranging study of vonoprazan, a novel potassium-compeitive acid blocker, versus lansoprazole for the treatment of erosive eshophagitis. Aliment Pharmacol Ther 2015. doi: 10.1111/apt.13331.
20. Nagashima H, Ikushima I,. Evaluation of pharmacodynamics and pharmacokinetics of esomeprazole 10, 20 and 40 mg and omeprazole 10 and 20 mg in Japanese healthy male subjects [In Japanese]. J Clin Therap Med 2011; 27: 735-46.
21. Hayato S, Hasegawa S, Hojo S, et al,. Dose-response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes. Eur J Clin Pharmacol 2012; 68: 579-88.
22. Saitoh T, Fukushima Y, Otsuka H, et al,. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment Pharmacol Ther 2002; 16: 1811-7.
23. Shimatani T, Inoue M, Kuroiwa T, et al,. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19. Clin Pharmacol Ther 2006; 79: 144-52.
24. Adachi K, Katsube T, Kawamura A, et al,. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 2000; 14: 1259-66.
25. Fass R, Shapiro M, Dekel R, et al,. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease-where next? Aliment Pharmacol Ther 2005; 22: 79-94.
26. Peghini PL, Katz PO, Bracy NA, et al,. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93: 763-7.
27. Desta Z, Zhao X, Shin JG, et al,. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 913-58.